Swiss Nordic Bio 2026: With a global footprint, Pilatus Biosciences is going after numerous first in class targets
Co-Founder Raven Lin walks us through the company's pipeline, which includes a clinical stage CD36 for GI cancers (and later for chronic liver disease), and IL-10 IO asset, and more.
Coverage brought to you by










.png)